ReviewJournal of clinical medicine2022

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.

Robert D Little et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.